Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Sierra Oncology

Status and phase: Terminated; Phase 2

Conditions: Polycythemia Vera; Essential Thrombocythemia

Treatments: Drug: Momelotinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT01998828

GS-US-354-0101

2013-004105-11 (EudraCT Number)

Details and patient eligibility

About

This open-label study is to determine the safety and efficacy of momelotinib in participants with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet received treatment with a Janus kinase (JAK) inhibitor.

Enrollment: 39 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of either PV or ET as defined by the 2008 World Health Organization (WHO) Diagnostic Criteria
• Requires treatment for PV or ET, in the opinion of the study investigator
• Intolerant of, resistant to, or refuses current or available treatment for PV or ET
• Direct bilirubin ≤ 2.0 x upper limit of the normal range (ULN)
• Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN
• Calculated creatinine clearance (CrCl) of ≥ 45 mL/min
• Life expectancy > 24 weeks
• Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
• Females who are nursing must agree to discontinue nursing before the first dose of study drug
• Able to comprehend and willing to sign informed consent form

Exclusion criteria

• Prior splenectomy
• Uncontrolled intercurrent illness, per protocol
• Known positive status for human immunodeficiency virus (HIV)
• Chronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier
• Myeloproliferative neoplasm-directed therapy, other than aspirin, hydroxyurea, anagrelide, and/or phlebotomy, within 21 days prior to the first dose of study drug
• Anagrelide within 7 days prior to the first dose of study drug
• Presence of peripheral neuropathy ≥ Grade 2
• Unwilling or unable to take oral medication
• Prior use of a JAK1 or JAK2 inhibitor
• Use of strong CYP3A4 inducers within 1 week prior to the first dose of study drug
• QTc interval > 450 msec, unless attributed to bundle branch block

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

39 participants in 4 patient groups

Momelotinib 100 mg PV

Experimental group

Description:

Participants with polycythemia vera will receive 100 mg of momelotinib.

Treatment:

Drug: Momelotinib

Momelotinib 200 mg PV

Experimental group

Description:

Participants with polycythemia vera will receive 200 mg of momelotinib.

Treatment:

Drug: Momelotinib

Momelotinib 100 mg ET

Experimental group

Description:

Participants with essential thrombocythemia will receive 100 mg of momelotinib.

Treatment:

Drug: Momelotinib

Momelotinib 200 mg ET

Experimental group

Description:

Participants with essential thrombocythemia will receive 200 mg of momelotinib.

Treatment:

Drug: Momelotinib